LOTTE BIOLOGICS Signs MoU with MilliporeSigma for Biologics Manufacturing
July 1, 2022
LOTTE BIOLOGICS, new biologics business of LOTTE group, signed a Memorandum of Understanding (MoU) with MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germanay, a leading science and technology company, outlining a collaboration to establish LOTTE’s biologics manufacturing capabilities in the USA. With this agreement, MilliporeSigma will be the first supplier to provide LOTTE with consulting, training, technical expertise, products, technologies, and manufacturing solutions.
The Life Science business of Merck KGaA, Darmstadt, Germany has well over 30 years’ experience in process development and GMP manufacturing. The company has helped bring more than 280 biologics to market and has released more than 100 GMP drug substances since 2012 across a range of molecules and scales.